Scarica l'app Stockscreener
39.60
17.02%
5.76
Dopo l'orario di chiusura:
39.55
-0.05
-0.13%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRNA Giù?
Forum
Previsione
Precedente Chiudi:
$33.84
Aprire:
$34.38
Volume 24 ore:
24.60M
Relative Volume:
2.28
Capitalizzazione di mercato:
$15.47B
Reddito:
$3.14B
Utile/perdita netta:
$-3.36B
Rapporto P/E:
-4.5361
EPS:
-8.73
Flusso di cassa netto:
$-4.03B
1 W Prestazione:
+11.05%
1M Prestazione:
+34.42%
6M Prestazione:
+17.72%
1 anno Prestazione:
+12.66%
Intervallo 1D:
$34.05
$39.71
Intervallo di 1 settimana:
$32.37
$39.71
Portata 52W:
$22.28
$45.40
Moderna Inc Stock (MRNA) Company Profile
Nome
Moderna Inc
Settore
Industria
Telefono
(617) 714-6500
Indirizzo
325 BINNEY STREET, CAMBRIDGE
Confronta MRNA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
39.60 | 13.22B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
454.67 | 116.86B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
758.91 | 80.72B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
810.51 | 49.26B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
369.96 | 49.00B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
351.06 | 36.96B | 4.98B | 69.59M | 525.67M | 0.5197 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-07 | Ripresa | UBS | Neutral |
| 2025-12-12 | Iniziato | Jefferies | Hold |
| 2025-03-13 | Iniziato | Citigroup | Neutral |
| 2025-02-18 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Downgrade | Goldman | Buy → Neutral |
| 2024-12-18 | Downgrade | Argus | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-19 | Iniziato | Berenberg | Hold |
| 2024-11-18 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-09-13 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Downgrade | Jefferies | Buy → Hold |
| 2024-09-13 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Downgrade | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Iniziato | Canaccord Genuity | Hold |
| 2023-11-03 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Downgrade | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-06-26 | Aggiornamento | UBS | Neutral → Buy |
| 2023-04-26 | Iniziato | Guggenheim | Neutral |
| 2023-03-13 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-02-24 | Downgrade | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-12-14 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Aggiornamento | Redburn | Sell → Neutral |
| 2022-01-26 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Iniziato | UBS | Neutral |
| 2021-12-07 | Iniziato | Cowen | Market Perform |
| 2021-11-09 | Iniziato | Wolfe Research | Outperform |
| 2021-10-22 | Iniziato | Deutsche Bank | Sell |
| 2021-10-15 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Reiterato | Jefferies | Hold |
| 2021-02-01 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Downgrade | Jefferies | Buy → Hold |
| 2020-12-16 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Downgrade | Needham | Buy → Hold |
| 2020-11-23 | Iniziato | Wells Fargo | Equal Weight |
| 2020-11-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Iniziato | Jefferies | Buy |
| 2020-06-30 | Iniziato | Argus | Buy |
| 2020-06-08 | Iniziato | Barclays | Overweight |
| 2020-04-30 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-05 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Ripresa | BofA/Merrill | Buy |
| 2019-10-25 | Iniziato | ROTH Capital | Buy |
| 2019-04-05 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Moderna Inc Borsa (MRNA) Ultime notizie
Adobe stock downgraded, Moderna surges on upbeat guidance - Yahoo Finance
Moderna (NASDAQ:MRNA) Shares Up 7.1%Still a Buy? - MarketBeat
Moderna rallies after projecting better-than-expected 2025 sales - Sherwood News
Why Moderna Stock Strength Is Only Beginning: Technical Analysis - Barron's
Silver Jumps To $89 After Soft CPI, JPMorgan Falls 3%: What's Moving Markets Tuesday? - Benzinga
Moderna (MRNA) Shares Surge by Nearly 13% - GuruFocus
Moderna, Kosmos Energy, Option Care Health, Kennametal And Other Big Stocks Moving Higher On Tuesday - Benzinga
Moderna stock jumps 12% after $1.9 billion 2025 sales view — what investors watch next - TechStock²
Moderna jumps 12% on 2025 projections - breakingthenews.net
Moderna: V940/Keytruda Data And Vaccine Revenues Drive A High-Risk Recovery Story (MRNA) - Seeking Alpha
Moderna updates 2025 outlook and highlights pipeline progress - The Globe and Mail
Moderna says possible allergic reactions to Covid-19 vaccine under investigation - The Daily Star
Moderna Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference - The Providence Journal
Moderna chair says US assault on science is just beginning - The Daily Gazette
Commonwealth Fusion Systems Appoints Stephane Bancel, Moderna CEO, to Its Board of Directors - energynews
The mRNA Pivot: Moderna Navigates Regulatory Headwinds and Tariff Turmoil in a Volatile 2026 Biotech Landscape - The Chronicle-Journal
Moderna Chair Says US Assault on Science Is Just Beginning - Bloomberg.com
Commonwealth Fusion Systems Appoints Stephane Bancel To Board - citybiz
Moderna expects 2025 revenue of $1.9B, above guidance - Proactive financial news
Aug Decliners: Should you avoid Moderna Inc stock right now2025 Biggest Moves & High Win Rate Trade Alerts - baoquankhu1.vn
Goldman Sachs Adjusts Price Target on Moderna to $36 From $33, Maintains Neutral Rating - marketscreener.com
Why Moderna Stock Is Dropping After Good News - Barron's
Moderna Sees 2025 Revenue Close to Outlook Range, Affirms Growth Target For This Year - marketscreener.com
Moderna Hits 2025 Revenue Goal as Operating Costs Fall Faster than Forecast - BioSpace
Moderna says its expects $1.9 billion in 2025 sales amid better-than-expected vaccination rate - Sherwood News
Moderna raises its forecasts and the stock rises before the opening of the US market - المتداول العربي
Moderna sees sales boost as COVID shots beat expectations - The Detroit News
Market movers: Synchrony Financial, Capital One, NextSource Materials, Moderna... - Proactive financial news
Moderna (MRNA) Projects Up to 10% Revenue Growth by 2026 - GuruFocus
Moderna stock rises. Revenue in 2025 will be higher than midpoint of guidance - MSN
Moderna updates on business and pipeline at JPM conference - The Pharma Letter
Moderna Stock Rises. Revenue in 2025 Will Be Higher Than Midpoint of Guidance. - Barron's
Moderna reiterates target of up to 10% revenue growth in 2026 (MRNA:NASDAQ) - Seeking Alpha
Moderna expects sales near upper end of 2025 forecast - Business Day
Moderna expects $1.9 billion revenue for 2025, exceeds cost targets By Investing.com - Investing.com India
Moderna sees sales boost as Covid-19 shots beat expectations - The Edge Malaysia
Moderna expects full-year 2025 revenue of $1.9B - breakingthenews.net
Moderna expects 2025 revenue of about $1.9 billion - marketscreener.com
Moderna climbs on $1.9 billion 2025 sales forecast - TradingView — Track All Markets
Moderna stock rises as revenue outlook exceeds estimates By Investing.com - Investing.com Canada
Moderna expects $1.9 billion in sales, trims costs forecast for 2025 - Reuters
Moderna raises 2025 revenue forecast to $1.9 billion - StreetInsider
Moderna chair warns of ‘dystopia’ amid US science pullback - Semafor
CEPI to Fund Pivotal Phase 3 Trial for Moderna's mRNA Pandemic Influenza Vaccine Candidate - St. Cloud Times
The mRNA Rivalry in 2026: A Tale of Financial Fortress Versus Speculative Despair - AD HOC NEWS
Moderna Vaccine (Spikevax) Review: Why This COVID-19 Shot Still Matters in 2026 - AD HOC NEWS
SG Americas Securities LLC Has $7.46 Million Holdings in Moderna, Inc. $MRNA - MarketBeat
Moderna Analyst Day Highlights Pipeline Progress and Business Strategy Updates - Lincoln Courier
Moderna Announces Data to be Presented at the 2025 International Congress of Inborn Errors of Metabolism - Greenville Online
Moderna’s Second Act: A 2026 Deep Dive into the Future of mRNA Therapeutics - FinancialContent
Moderna (MRNA) Stock Sinks As Market Gains: Here's Why - sharewise.com
Moderna Inc Azioni (MRNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.73%
2.37%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):